Clinical Trials
6 trialsNCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT00597597 2023-05-17
Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer
Rush University Medical Center
Phase 2 Terminated
NCT00570258 2021-03-30
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
University of Arkansas
Phase 2 Terminated
NCT00503841 2019-04-30
Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
Barbara Ann Karmanos Cancer Institute
Phase NA Terminated
NCT00611715 2012-08-09
Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00739063 2012-03-15
Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated